Phase II study of intravenous idarubicin in unfavorable non-hodgkin's lymphoma

Idarubicin, a new analogue of daunorubicin, was administered i.v. at a dose of 15 mg/m2 to 31 previously treated patients with unfavorable non-Hodgkin's lymphoma. Clinical characteristics included median age, 69 years; performance status, 1; and prior chemotherapeutic regimens, 1. Twenty of the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 1992-07, Vol.52 (14), p.3871-3874
Hauptverfasser:	CASE, D. C, GERBER, M. C, GAMS, R. A, CRAWFORD, J, VOTAW, M. L, HIGANO, C. S, PRUITT, B. T, GOULD, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Agranulocytosis - chemically induced Antineoplastic agents Biological and medical sciences Chemotherapy Drug Administration Schedule Drug Evaluation Female Heart Diseases - chemically induced Humans Idarubicin - adverse effects Idarubicin - therapeutic use Infusions, Intravenous Lymphoma, Non-Hodgkin - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!